Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study on Intima Media Thickness (IMT) in Middle-aged Subjects

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00784264
First received: October 22, 2008
Last updated: January 11, 2010
Last verified: January 2010

October 22, 2008
January 11, 2010
October 2008
Not Provided
To investigate the prevalence of asymptomatic atherosclerosis by measurement of intima media thickness (IMT) in middle-aged subjects with central obesity in Hong Kong, [ Time Frame: during the one single study visit ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00784264 on ClinicalTrials.gov Archive Site
  • To examine the association between IMT value and cardiovascular disease (CVD) risk factors, and blood lipid and glucose profiles in middle-aged centrally obese subjects in Hong Kong. [ Time Frame: During the one single study visit ] [ Designated as safety issue: No ]
  • IMT results to be compared with what being reported in the recent literature on normal Chinese population. [ Time Frame: During the one single study visit ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study on Intima Media Thickness (IMT) in Middle-aged Subjects
A Study on Intima Media Thickness (IMT) in Middle-aged Subjects

This is an observational study to measure the thickness of artery walls in the neck (intima media thickness IMT) by ultrasound examination in middle-aged subjects with central obesity. The purpose of this study is to obtain local data how common asymptomatic atherosclerosis is, and to investigate the association between Cardiovascular Disease risk factors and intima media thickness (IMT) in the Hong Kong population. Results from this study may enhance the public awareness of asymptomatic atherosclerosis and understand its role in the development of Cardiovascular Disease in Hong Kong.

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

aged 55 or above with central obesity, male more than 90 cm; female more than 80 cm

Atherosclerosis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
June 2009
Not Provided

Inclusion Criteria:

  • Male or female aged 55 years or above.
  • Waist circumference: male more than 90 cm; female more than 80 cm.

Exclusion Criteria:

  • Any known chronic diseases requiring long-term medication such as hypertension, diabetes and hyperlipidemia.
  • Presence of known cardiovascular diseases including cerebro-vascular disease, coronary heart disease and peripheral artery disease.
  • Presence of any active major diseases that may interfere the physical conditions and body weight of subjects during the study period, which include malignancy, infection, renal or liver function impairment, recent major surgery (within 3 months).
Both
45 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Hong Kong
 
NCT00784264
NIS-CHK-DUM-2008/1
No
Karen Yuen, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Study Director: Karen Yuen AstraZeneca Hong Kong Ltd
Principal Investigator: Chun chung Chow, MD Prince of Wales Hospital, Shatin, Hong Kong
AstraZeneca
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP